Medtronic to Acquire Intersect ENT for ~$1.1B

Share this

Medtronic to Acquire Intersect ENT for ~$1.1B


  • Medtronic to acquire all outstanding shares of Intersect ENT for $28.25/ share in cash- making a total deal value of ~$1.1B. The transaction is expected to be completed by H1’22
  • The acquisition will expand Medtronic’s product portfolio which is used in the ENT procedure. Additionally- the acquisition will add a bioabsorbable drug release platform to the CRS portfolio
  • Intersect ENT's PROPEL and SINUVA sinus implants will combine with Medtronic’s navigation- powered instruments- and existing tissue health products to provide solutions for patients suffering from CRS

  | Ref: PR Newswire | Image: Rasayanika

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions